RxDoctor Payments Data

Timothy Patterson, DO

Internal Medicine · Bryn Mawr, PANPI 1902132871

Payments from drug & device makers

$5,728in general payments, 2019–2025

Across 323 payments — averaging $17.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Lilly USA, LLC$466
  • Pfizer$441
  • AbbVie$437
  • Boehringer Ingelheim$398
  • AstraZeneca$262
  • plus $3K from 35 others

What the payments were for

  • Speaking & faculty fees$531%
  • Food & beverage$5,67599%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,728 in reported general payments places this provider in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$45,757
Medicare patients
233
Services billed
612

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate46$52,207
JardianceEmpagliflozin35$37,370
EliquisApixaban32$33,112
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$14,956
OzempicSemaglutide15$14,024
FarxigaDapagliflozin Propanediol21$12,126
Breo ElliptaFluticasone/Vilanterol15$8,466
Atorvastatin Calcium385$5,267
Serevent DiskusSalmeterol Xinafoate11$4,960
Lantus SolostarInsulin Glargine,hum.Rec.Anlog22$4,042
Venlafaxine Hcl ErVenlafaxine Hcl26$2,963
VascepaIcosapent Ethyl15$2,629
Rosuvastatin Calcium108$2,572
Amlodipine Besylate285$2,473
Omeprazole126$2,324

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$177$52,20746 claims
Boehringer IngelheimJardiance$398$37,37035 claims
PfizerEliquis$441$33,11232 claims
GSKTrelegy Ellipta, Breo Ellipta$190$23,42133 claims
Novo NordiskOzempic$1,165$14,02415 claims
AstraZenecaFarxiga$262$12,12621 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Bryn Mawr

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →